About
Dr Sarah Cole is Chief Executive Officer of SENISCA, a University of Exeter spinout developing RNA-based senotherapeutics to reverse cellular senescence and treat age-related disease. She joined SENISCA as Chief Operating Officer in March 2023 and was appointed CEO on November 2, 2023, leading strategic development, communications, and investor liaison. SENISCA states that she previously held senior research roles at Takeda and Transine Therapeutics and worked in life sciences investment at Takeda Ventures.
Areas of interest
longevitybiotechRNA therapeuticssenescenceage-related diseaseoligonucleotide therapeuticsearly-phase biotechstrategic developmentinvestor relationslife sciences